RELEVIUM TECHNOLOGIES INC

RELEVIUM TECHNOLOGIES INC

OOTC:RLLVF
0.00
USD
0.00
(0.00%)
RELEVIUM TECHNOLOGIES INC
OTC:RLLVF
(OTC Markets)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available
Business
Relevium Technologies Inc. Relevium Technologies Inc. (TSXV:RLV, OTCQB:RLLVF) is a Canada-based wellness portfolio company that identifies, evaluates, acquires, and operates brands and businesses in the health and wellness sector, with a primary focus on online distribution of nutraceuticals, sports nutrition, and nutri-cosmeceuticals; it operates through wholly-owned subsidiaries including BGX E-Health LLC, based in Orlando, Florida, which offers premium brands such as Bioganix, PushandPullsystem, and LeefyLyfe encompassing dietary supplements, skincare, fitness products, and consumer packaged goods distributed via major retailers like Amazon and Walmart in the US and Europe, and Biocannabix Health Corporation, which develops pediatric endo-medicinal nutraceuticals for cannabinoid therapy targeting medical cannabis markets. Founded around 2015 and headquartered at 1000 Sherbrooke Street West, Suite 2700, Montreal, Quebec, the company pursues growth through an acquisition model in consumer packaged goods, pediatric biopharma, and corporate segments, with operations spanning North America, Europe, and strategic pursuits in Latin America including Colombia. Recent developments include the completion of shares-for-debt transactions involving AIP acquiring over 65 million common shares, ongoing management cease trade order updates with bi-weekly progress disclosures as of early 2022, securing PPE contracts totaling $16 million that drove record Q2 revenues and FYE June 30, 2022 earnings, an agreement to acquire 100% of Terry Booth’s MED PPE Canada to strengthen joint venture operations, and subsidiary BGX E-Health securing a $1 million export contract for the Middle East, alongside historical expansions like positioning Biocannabix in Colombia for endo-medical cannabis and pursuing Lifeline Pharma acquisition for EU-GMP extraction and cultivation capabilities.